Back to News
Market Impact: 0.3
Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer
Source: PR Newswire
Healthcare & BiotechRegulation & Legislation
Akeso announced that ivonescimab plus chemotherapy for first-line treatment of locally advanced or metastatic biliary tract cancer has been granted Priority Review in China. The article excerpt provides no trial results, approval decision, or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- South Korea’s KOSPI halts trade after 8% wipeout on AI losses
- U.S. stock futures rise after AI rout batters Wall St; payrolls data in focus
- ’Our phones are exploding’: Goldman Sachs dissects historic Wall Street crash
- Top Democrats call to rein in AI buildout after midterms sweep: 'National data center moratorium now'